Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

326P - National multicentre retrospective study on metastatic breast cancer patients to characterize long responder under eribulin: LORELINE study

Date

16 Sep 2021

Session

ePoster Display

Presenters

Marie Ange Mouret Reynier

Citation

Annals of Oncology (2021) 32 (suppl_5): S457-S515. 10.1016/annonc/annonc689

Authors

M.A. Mouret Reynier1, M. Paillard2, L. Uwer3, I. MOLNAR4, F. KWIATKOWSKI4, S. LUSHO4, N. Dohollou5, T. Petit6, N. Hajjaji7, L. Boudin8, V. Lorgis9, J.P. JACQUIN10, C. Abrial4, J. PASSILDAS JAHANMOHAN4

Author affiliations

  • 1 Medical Oncology, Jean Perrin Center, 63011 - Clermont-Ferrand/FR
  • 2 Medical Oncology, CHRU Besancon - Hopital Jean Minjoz, 25030 - Besançon/FR
  • 3 Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, 54519 - Vandoeuvre les Nancy/FR
  • 4 Division De Recherche Clinique, Jean Perrin Center, 63011 - Clermont-Ferrand/FR
  • 5 Medical Oncology, Polyclinique Bordeaux Nord Aquitaine, 33077 - Bordeaux/FR
  • 6 Medical Oncology, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 7 Medical Oncology, Centre Oscar Lambret, 59020 - Lille/FR
  • 8 Medical Oncology, Hôpital d'Instruction des Armées (HIA) Ste Anne, 83000 - Toulon/FR
  • 9 Oncologue Medical, Institut Cancérologie de Bourgogne, 21000 - Dijon/FR
  • 10 Medical Oncology, Institut de Cancérologie Lucien Neuwirth, 42270 - Saint-Étienne/FR
More

Abstract 326P

Background

Eribulin (ERI) can respresent a therapeutic alternative for advanced breast cancer patients (pts) who have received at least one or two lines of anthracyclines-based chemotherapy and taxanes therapy. In this study, we focused on long responder patients, i.e. with objective response or stability ≥ 6 months (mo.) under ERI, in order to better characterize them.

Methods

Metastatic breast cancer pts treated by ERI in 2nd, 3rd or 4th line between Sep-2011 and June-2018 were selected. The following parameters were assessed: primary tumor and metastasis characteristics, type of response and duration, disease progression, treatment received, toxicities, survival (progression free survival (PFS), overall survival (OS)) and predictive factors of PFS. A special focus was set on pts with hepatic disease (HD).

Results

Among the 98 pts included, analysis was conducted on 84 pts (median age 62) with a majority of HR+ tumor (89% HR+; 6% TN and 5% unknown), 81% of pts had visceral disease and 89% had non visceral disease. ERI was received in 2nd, 3rd and 4th line of metastatic treatment for respectively 21%, 44% and 35% pts. Complete response (CR), partial response (PR) and stable disease (SD) were observed respectively for 2.4%, 46.4% and 51.2% of pts. The median duration of response was 25.6 weeks (95 IC 22-27.7) with a median number of infusions of 6. Response was similar irrespective of ERI line number. HD was observed in 70.2% of pts with 3.4% of CR, 50.8% of PR and 45.8% of SD. The median PFS was 9 mo. (95 %CI 8-10). Subgroup analysis showed similar PFS irrespective of HD (p=0.21) and treatment line (p=0.46). The median OS was 24 mo. (95% IC 20-31). Predictive factors of PFS in univariate analysis were progesterone receptor expression (p=0.014), number of ERI infusions (p=0.011) and duration of response (p<0.001); in multivariate analysis the main predictive factor was duration of response (p=0.003). The same predictive factors were found for pts with HD.

Conclusions

Response to ERI and PFS were independent of presence of hepatic metastasis and number of line by ERI. The duration of response, number of line by ERI and positive progesterone receptor are the main predictive factors of PFS in our cohort and in pts with HD.

Clinical trial identification

NCT03771183.

Editorial acknowledgement

Legal entity responsible for the study

Centre Jean Perrin.

Funding

Eisai.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings